Stable corneal endothelial cell (CEC) compositions and methods of use
Incorporating a ROCK inhibitor in a composition with cultured human corneal endothelial cells and storing at specific temperatures maintains cell viability and functionality, addressing the need for improved treatment methods by extending shelf-life and ensuring effective therapeutic use.
WO2026128800A1PCT designated stage Publication Date: 2026-06-18AURION BIOTECH INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- AURION BIOTECH INC
- Filing Date
- 2025-12-12
- Publication Date
- 2026-06-18
Smart Images
Figure US2025059378_18062026_PF_FP_ABST
Abstract
Provided are stable cell compositions comprising a population of cultured human corneal endothelial cells (CECs) and a rho kinase (ROCK) inhibitor. The stable cell composition has improved stability, e.g., at least 70% cell viability following 7 days of storage at 20 degrees Celsius. The stable cell compositions can be used in CEC therapies to treat corneal endothelial diseases.
Need to check novelty before this filing date? Find Prior Art